Results 31 to 40 of about 5,464 (192)
Development of Reference Intervals for the TEG 6s, a Point-of-Care Viscoelastic Assay, in Dogs. [PDF]
Vet Clin PatholABSTRACT Background Thromboelastography (TEG) provides a global assessment of hemostasis and identifies patients with both hemorrhagic and thrombotic tendencies. Traditional TEG instruments, such as the TEG 5000 (Haemonetics), can be labor‐intensive and require specialized training to operate.
Wilkinson AR, Conner BJ, Serpa PBS.
europepmc +2 more sources
Rationale for intracoronary administration of abciximab
, 2007 The present review aims to describe the pharmacological aspects as well as the available clinical data supporting the choice of intracoronary route of administration for abciximab, an antiplatelet drug used in patients with acute coronary syndromes ...
Trani C. +3 more
core +2 more sources
Intracoronary abciximab in STEMI using local drug delivery catheter – Single center experience
Indian Heart Journal, 2013 Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm.
G. Sengottuvelu, V. Ravi Sekar
doaj +1 more source
Cardiovascular Ultrasound, 2012 Background Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis.
Kretzschmar Daniel +9 more
doaj +1 more source
Establishment of Haemonetics TEG 6s Reference Interval in Healthy Dogs
Veterinary Clinical Pathology, EarlyView.ABSTRACT Background A thromboelastogram viscoelastic monitor (the TEG 6s) has recently become available for use in veterinary patients. It is therefore necessary to establish reference intervals for the new device in each species where it is employed.
Kaylan Whetstone +6 more
wiley +1 more source
Acta Ortopédica Brasileira, 2000 O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj +1 more source
Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy
Advanced Science, Volume 13, Issue 39, 13 July 2026.Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee +11 more
wiley +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2020 Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible
Xiaolin Zhu MD, Genmao Cao MD
doaj +1 more source
Brain and Behavior, Volume 16, Issue 6, June 2026.Graphical representation of the comparative efficacy and safety of intravenous tirofiban for acute ischemic stroke in randomized controlled trials. ABSTRACT Background: Tirofiban is a GP IIb/IIIa inhibitor, an anti‐platelet drug that is used in ischemic stroke or acute coronary syndromes.
Dorothy Lim Bullecer +12 more
wiley +1 more source
, 2008 Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI).
N. d. Cesare +17 more
core +1 more source